CJ Godfrey, Ph.D.

Vice President, Strategic Business Development

CJ has 18 years of drug development experience in both pharma and consulting roles and has been applying pharmacometric methods to PK/PD/outcome analysis and decision support for 22 years. His clinical experience spans a broad range of biomarker, safety, and efficacy endpoints with particular emphasis on oncology, rare diseases, inflammation, and viral diseases. He has extensive experience in performing model-based meta-analyses and near-real-time population PK/PD modeling to support informed and timely decision making.

Recent publications by this scientist

Pharmacokinetic Modeling of Intrathecally Administered Recombinant Human Arylsulfatase A (TAK‐611) in Children With Metachromatic Leukodystrophy

June 1, 2020

Troy S, Wasilewski M, Beusmans J, Godfrey CJ.  Clin Pharmacol Ther. 2020 Jun;107(6):1394-1404. doi: 10.1002/cpt.1752. Epub 2020 Feb 25. PMID: 31868225; PMCID: PMC7325319.

View More

Pharmacokinetic & pharmacodynamic modeling and simulation of recombinant human arylsulfatase A in patients with metachromatic leukodystrophy: a preliminary evaluation

February 5, 2018

Troy S, Wasilewski M, Godfrey CJ. Poster presented at the 14th Annual WORLDSymposium. San Diego, CA. 5-9 February 2018.

Download PDF

Exposure-Response Modeling and Simulation to Support Evaluation of Efficacious and Safe Exposure and Dose Range for Asfotase Alfa in Patients With Hypophosphatasia

October 9, 2015

Pradhan RS, Gastonguay MR, Gao X, Monteleone JPR, Lathia CD, Fisher J, Godfrey C, Dirks NL, Melian A, Thompson DD.  Poster presented at ASBMR 2015 American Society for Bone and Mineral Research’s Annual Meeting. 9-12 October 2015.